Interest of Levosimendan Preconditioning for Cardiac Surgery Under CEC in

Status Recruiting

Clinical Trial Summary

Levosimendan, a drug with inotropic, vasodilatory and myocardial protective properties, has been proposed for the prevention and treatment of postoperative low cardiac output syndrome in cardiac surgery. Despite preliminary studies with promising results, large randomized controlled trials aimed at demonstrating the benefits of levosimendan did not show superiority over placebo in this indication. However, in these studies, the infusion was neither performed at the maximum dosage nor during the 24 hours preceding the surgery, but mainly at the very beginning of the operation. However, post hoc analyses showed a reduction in mortality and in the occurrence of low cardiac output syndrome in the subgroup of patients who had undergone isolated coronary artery bypass grafting, in contrast to those who had undergone valvular or combined surgery. Another recent study suggests that under similar conditions, preconditioning with levosimendan started 48 hours before surgery reduces the length of stay in intensive care and the average cost of hospitalization. There are no formal recommendations on the prophylactic use of levosimendan in cardiac surgery for heart failure patients with impaired LVAS. However, the France-Levo registry, a multicenter observational study requested by the HAS, has shown that in real practice there is a place for preconditioning with levosimendan, which is used in this indication for 7% of the patients in the registry. The Cardiovascular Surgery and Transplantation Department of the Nancy Brabois University Hospital, which actively participated in the France-Levo registry, is one of the cardiac surgery centers that uses this practice, as is the University Hospital of Rouen. It is interesting to be able to evaluate retrospectively whether levosimendan preconditioning has a positive impact on the postoperative prognosis of patients and more particularly on the reduction of the length of stay in critical care and in hospital compared to standard management.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cardiac Surgery
Heart Failure
Heart Failure With Reduced Ejection Fraction

Clinical Trial Details

NCT number	NCT06021587
Study type	Observational
Source	Central Hospital, Nancy, France
Contact	Thomas KLEIN, MD
Phone	+3383154045
Email	t.klein@chru-nancy.fr
Status	Recruiting
Phase
Start date	July 1, 2023
Completion date	October 10, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05054179` - Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain	Phase 2/Phase 3
Completed	`NCT04051021` - Non-Pharmacological Interventions on Patient Experience and Healthcare Utilization in Adult Cardiac Surgery Patients	N/A
Recruiting	`NCT04604886` - The Consistency of Cardiac Output Measured by Pulmonary Artery Catheter and LiDCO in Cardiac Surgical Patients	N/A
Recruiting	`NCT04075981` - Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)	Phase 3
Completed	`NCT04062396` - Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction	N/A
Recruiting	`NCT04709705` - DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)	Phase 2/Phase 3
Not yet recruiting	`NCT05563662` - SURgical Registry of ENDocarditis EuRope
Withdrawn	`NCT03289104` - Improving Sternal Healing After Cardiac Surgery: Sternal Wire vs ZIPFIX	N/A
Completed	`NCT04199039` - Effects of Endotracheal Tube Fixation Methods on Hemodynamic Parameters During Endotracheal Suction	N/A
Completed	`NCT03563196` - Diagnosis Of Pulmonary Complications After Cardiac Surgery In Children
Completed	`NCT02964026` - Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients	N/A
Completed	`NCT02471001` - The Levels of Anaesthetics in Heart Muscle During Heart Surgery	N/A
Completed	`NCT02325726` - RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery.	N/A
Completed	`NCT01246947` - Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Miral Operation	N/A
Completed	`NCT01151254` - Comparison of Propofol Based Versus Volatile Based Anesthesia and Postoperative Sedation	N/A
Completed	`NCT00821262` - Sevoflurane in Cardiac Surgery	Phase 4
Completed	`NCT00996099` - Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients	N/A
Completed	`NCT00617955` - Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates	N/A
Completed	`NCT00336466` - The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)	Phase 2
Completed	`NCT00337805` - Double Blind Randomized Trial of Saline vs Pentaspan for Resuscitation After Cardiac Surgery	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Interest of Levosimendan Preconditioning for Cardiac Surgery Under CEC in Heart Failure Patients With Impaired Ejection Fraction — LevoCV

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms